Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
39,496,494
-
Total 13F shares
-
14,910,095
-
Share change
-
+9,870,368
-
Total reported value
-
$76,226,105
-
Put/Call ratio
-
19%
-
Price per share
-
$5.14
-
Number of holders
-
45
-
Value change
-
+$50,694,989
-
Number of buys
-
34
-
Number of sells
-
14
Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock (VTGN) as of Q4 2023
As of 31 Dec 2023,
Vistagen Therapeutics, Inc. - Common Stock (VTGN) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,910,095 shares.
The largest 10 holders included
BVF INC/IL, GREAT POINT PARTNERS LLC, VANGUARD GROUP INC, Nantahala Capital Management, LLC, StemPoint Capital LP, COMMODORE CAPITAL LP, SPHERA FUNDS MANAGEMENT LTD., CITADEL ADVISORS LLC, ARMISTICE CAPITAL, LLC, and BlackRock Inc..
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.